Icotrokinra increases likelihood of Investigator's Global Assessment 0 or 1 by risk ratio 7.27
Icotrokinra Shows Promise for Moderate to Severe Plaque Psoriasis
This meta-analysis of icotrokinra for moderate-to-severe plaque psoriasis in adolescents and adults found a risk ratio of 7.27 for Investiga…
A new treatment called icotrokinra shows significant skin clearance and improved scores for adults and teens with moderate to severe plaque …
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
Oral icotrokinra shows strong results for moderate-to-severe plaque psoriasis
This systematic review and meta-analysis evaluates icotrokinra for moderate-to-severe plaque psoriasis in 1951 patients. The pooled analysis…
A new analysis finds oral icotrokinra helps clear skin faster than placebo in patients with moderate-to-severe plaque psoriasis.